Abstract
Doxorubicin is a widely used chemotherapeutic agent; however, its clinical uses are limited due to its cardiotoxicity associated with an induction of oxidative stress. This study was aimed to investigate the protective effect of hesperetin against doxorubicin-induced cardiotoxicity in rats. Doxorubicin was administered at the dosage of 4 mg/kg bw/week, ip for a period of 5 consecutive weeks. Hesperetin was administered at the dosages of 25, 50 and 100 mg/kg bw, po by gavage for 5 consecutive days in a week for 5 weeks. The animals were killed 1 week after the last injection of doxorubicin. Hesperetin at the doses of 50 and 100 mg/kg bw significantly reduced MDA and increased GSH levels in the doxorubicin-treated animals. Further, hesperetin significantly reduced doxorubicin-induced DNA damage as well as apoptosis at 25, 50, and 100 mg/kg bw as evident from the comet and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assays, respectively. Thus, hesperetin ameliorated doxorubicin-induced cardiotoxicity by reducing oxidative stress, abnormal cellular morphology and DNA damage in rat. Moreover, nuclear factor-kappa B, p38, and caspase-3 play a role in the hesperetin-mediated protection against doxorubicin-induced cardiotoxicity. This study indicates the protective effect of hesperetin against doxorubicin-induced cardiotoxicity.
Similar content being viewed by others
Abbreviations
- DOX:
-
Doxorubicin
- TUNEL:
-
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
- NFκB:
-
Nuclear factor-kappa B
- SD:
-
Sprague–Dawley
- CMC:
-
Carboxy methyl cellulose
- H&E:
-
Hematoxylin and eosin
- EtBr:
-
Ethidium bromide
- DMSO:
-
Dimethylsulfoxide
- NMPA:
-
Normal melting point agarose
- LMPA:
-
Low melting point agarose
- EDTA:
-
Ethylenediamine tetraacetic acid
- HBSS:
-
Hank’s balanced salt solution
- ip:
-
Intraperitoneal
- TL:
-
Tail length
- TM:
-
Tail moment
- OTM:
-
Olive tail moment
- % DNA:
-
% DNA in comet tail
- MDA:
-
Malondialdehyde
- GSH:
-
Reduced glutathione
References
Kim, J. C., Kim, K. H., & Chung, M. K. (1999). Testicular cytotoxicity of DA-125, a new anthracycline anticancer agent, in rats. Reproductive Toxicology, 13, 391–397.
Alkreathy, H., Damanhouri, Z. A., Ahmed, N., Slevin, M., Ali, S. S., & Osman, A. M. (2010). Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food and Chemical Toxicology, 48, 951–956.
Ludke, A. R., Al-Shudiefat, A. A., Dhingra, S., Jassal, D. S., & Singal, P. K. (2009). A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Canadian Journal of Physiology and Pharmacology, 87, 756–763.
Fan, G. C., Zhou, X., Wang, X., Song, G., Qian, J., Nicolaou, P., et al. (2008). Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circulation Research, 103, 1270–1279.
Simoncikova, P., Ravingerova, T., & Barancik, M. (2008). The effect of chronic doxorubicin treatment on mitogen-activated protein kinases and heat stress proteins in rat hearts. Physiological Research, 57(Suppl 2), S97–S102.
Liu, Z., Song, X. D., Xin, Y., Wang, X. J., Yu, H., Bai, Y. Y., et al. (2009). Protective effect of chrysoeriol against doxorubicin-induced cardiotoxicity in vitro. Chinese Medical Journal, 122, 2652–2656.
Chandran, K., Aggarwal, D., Migrino, R. Q., Joseph, J., McAllister, D., Konorev, E. A., et al. (2009). Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by Mito-Q. Biophysical Journal, 96, 1388–1398.
Li, L., Pan, Q., Han, W., Liu, Z., Li, L., & Hu, X. (2007). Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clinical Cancer Research, 13, 6753–6760.
Van Dalen, E. C., van der Pal, H. J., Caron, H. N., & Kremer, L. C. (2009). Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews, 4, CD005008.
Aiken, M. J., Suhag, V., Garcia, C. A., Acio, E., Moreau, S., Priebat, D. A., et al. (2009). Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging. Clinical Nuclear Medicine, 34, 762–767.
Gil-Izquierdo, A., Gil, M. I., Ferreres, F., & Tomas-Barberan, F. A. (2001). In vitro availability of flavonoids and other phenolics in orange juice. Journal of Agricultural and Food Chemistry, 49, 1035–1041.
Ameer, B., Weintraub, R. A., Johnson, J. V., Yost, R. A., & Rouseff, R. L. (1996). Flavanone absorption after naringin, hesperidin, and citrus administration. Clinical Pharmacology and Therapeutics, 60, 34–40.
Lee, N. K., Choi, S. H., Park, S. H., Park, E. K., & Kim, D. H. (2004). Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology, 71, 174–180.
Manach, C., Morand, C., Gil-Izquierdo, A., Bouteloup-Demange, C., & Remesy, C. (2003). Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. European Journal of Clinical Nutrition, 57, 235–242.
Galati, E. M., Trovato, A., Kirjavainen, S., Forestieri, A. M., Rossitto, A., & Monforte, M. T. (1996). Biological effects of hesperidin, a Citrus flavonoid. (Note III): Antihypertensive and diuretic activity in rat. Farmaco, 51, 219–221.
Garg, A., Garg, S., Zaneveld, L. J., & Singla, A. K. (2001). Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytotherapy Research, 15, 655–669.
Aranganathan, S., Selvam, J. P., & Nalini, N. (2008). Effect of hesperetin, a citrus flavonoid, on bacterial enzymes and carcinogen-induced aberrant crypt foci in colon cancer rats: A dose-dependent study. Journal of Pharmacy and Pharmacology, 60, 1385–1392.
Choi, E. J., & Ahn, W. S. (2008). Neuroprotective effects of chronic hesperetin administration in mice. Archives of Pharmacal Research, 31, 1457–1462.
Dimpfel, W. (2006). Different anticonvulsive effects of hesperidin and its aglycone hesperetin on electrical activity in the rat hippocampus in vitro. Journal of Pharmacy and Pharmacology, 58, 375–379.
Guthrie, N., & Carroll, K. K. (1998). Inhibition of mammary cancer by citrus flavonoids. Advances in Experimental Medicine and Biology, 439, 227–236.
Miyake, Y., Yamamoto, K., Tsujihara, N., & Osawa, T. (1998). Protective effects of lemon flavonoids on oxidative stress in diabetic Rats. Lipids, 33, 689–695.
Saija, A., Scalese, M., Lanza, M., Marzullo, D., Bonina, F., & Castelli, F. (1995). Flavonoids as antioxidant agents: Importance of their interaction with biomembranes. Free Radical Biology and Medicine, 19, 481–486.
Nagi, M. N., & Mansour, M. A. (2000). Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: A possible mechanism of protection. Pharmacological Research, 41, 283–289.
Aranganathan, S., Selvam, J. P., & Nalini, N. (2009). Hesperetin exerts dose dependent chemopreventive effect against 1, 2-dimethyl hydrazine induced rat colon carcinogenesis. Investigational New Drugs, 27, 203–213.
Ohkawa, H., Ohishi, N., & Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry, 95, 351–358.
Moron, M. S., Depierre, J. W., & Mannervik, B. (1979). Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochimica et Biophysica Acta, 582, 67–78.
Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
Vikram, A., Tripathi, D. N., Ramarao, P., & Jena, G. B. (2008). Intervention of d-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicology and Applied Pharmacology, 226, 84–93.
Kasamatsu, T., Kohda, K., & Kawazoe, Y. (1996). Comparison of chemically induced DNA breakage in cellular and subcellular systems using the comet assay. Mutation Research, 369, 1–6.
Speit, G., & Hartmann, A. (1999). The comet assay (single-cell gel test). A sensitive genotoxicity test for the detection of DNA damage and repair. Methods in Molecular Biology, 113, 203–212.
Singh, N. P. (2000). A simple method for accurate estimation of apoptotic cells. Experimental Cell Research, 256, 328–337.
Lebrecht, D., Geist, A., Ketelsen, U. P., Haberstroh, J., Setzer, B., & Walker, U. A. (2007). Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. British Journal of Psychiatry, 151, 771–778.
Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., & Gersl, V. (2009). Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 61, 154–171.
Su, Y. W., Liang, C., Jin, H. F., Tang, X. Y., Han, W., Chai, L. J., et al. (2009). Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy. Circulation Journal, 73, 741–749.
Iqbal, M., Dubey, K., Anwer, T., Ashish, A., & Pillai, K. K. (2008). Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacological Reports, 60, 382–390.
L’Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., et al. (2006). DNA damage is an early event in doxorubicin-induced cardiac myocyte death. American Journal of Physiology, 291, H1273–H1280.
Chao, H. H., Liu, J. C., Hong, H. J., Lin, J. W., Chen, C. H., & Cheng, T. H. (2011). L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. International Journal of Cardiology, 146, 145–152.
Li, N., & Karin, M. (1999). Is NF-kappaB the sensor of oxidative stress? The Faseb Journal, 13, 1137–1143.
Wang, S., Kotamraju, S., Konorev, E., Kalivendi, S., Joseph, J., & Kalyanaraman, B. (2002). Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochemical Journal, 367, 729–740.
Liu, J., Mao, W., Ding, B., & Liang, C. S. (2008). ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. American Journal of Physiology, 295, H1956–H1965.
Lou, H., Danelisen, I., & Singal, P. K. (2005). Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. American Journal of Physiology, 288, H1925–H1930.
Kim, J. Y., Jung, K. J., Choi, J. S., & Chung, H. Y. (2006). Modulation of the age-related nuclear factor-kappaB (NF-kappaB) pathway by hesperetin. Aging Cell, 5, 401–411.
Sardao, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2009). Morphological alterations induced by doxorubicin on H9c2 myoblasts: Nuclear, mitochondrial, and cytoskeletal targets. Cell Biology and Toxicology, 25, 227–243.
Zhang, S. H., Wang, W. Q., & Wang, J. L. (2009). Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo. Acta Pharmacologica Sinica, 30, 1479–1487.
Hwang, S. L., & Yen, G. C. (2008). Neuroprotective effects of the citrus flavanones against H2O2-induced cytotoxicity in PC12 cells. Journal of Agricultural and Food Chemistry, 56, 859–864.
Choi, E. J., & Kim, G. H. (2011). Anti-/pro-apoptotic effects of hesperetin against 7, 12-dimetylbenz(a)anthracene-induced alteration in animals. Oncology Reports, 25, 545–550.
Ali, M. M., Agha, F. G., El-Sammad, N. M., & Hassan, S. K. (2009). Modulation of anticancer drug-induced P-glycoprotein expression by naringin. Zeitschrift für Naturforschung Section C, 64, 109–116.
Hsiao, Y. C., Hsieh, Y. S., Kuo, W. H., Chiou, H. L., Yang, S. F., Chiang, W. L., et al. (2007). The tumor-growth inhibitory activity of flavanone and 2′-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs. Journal of Biomedical Science, 14, 107–119.
Choi, E. J. (2007). Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: Involvement of CDK4 and p21. Nutrition and Cancer, 59, 115–119.
Masoodi, T. A., & Alhamdanz, A. H. (2010). Inhibitory effect of flavonoids on mutant H-Rasp protein. Bioinformation, 5, 11–15.
Acknowledgments
We wish to acknowledge the financial assistance received from National Institute of Pharmaceutical Education and Research (NIPER), Mohali, to undertake this study. The authors would also like to acknowledge Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, for benevolently granting the gift sample of doxorubicin.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trivedi, P.P., Kushwaha, S., Tripathi, D.N. et al. Cardioprotective Effects of Hesperetin against Doxorubicin-Induced Oxidative Stress and DNA Damage in Rat. Cardiovasc Toxicol 11, 215–225 (2011). https://doi.org/10.1007/s12012-011-9114-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-011-9114-2